M. Byrd

Marshall P. Byrd, Ph.D.

Patent Agent

Prior to joining Parker Highlander, Marshall gained over 8 years of practice experience as a patent agent and technical advisor with the law firms of Fulbright & Jaworski LLP and Marshall Gerstein & Borun LLP. He has extensive experience in U.S. and foreign patent prosecution on behalf of a wide range of clients, including academic institutions, startups and Fortune 500 biotechnology and pharmaceutical companies. He provides strategic advice regarding intellectual property portfolio development as well as freedom to operate and IP landscape searches and analyses. He has experience working with a wide range of technologies including pharmaceuticals, biomedical and microfluidic devices, biofuel production and agricultural biotechnology.

Areas of Concentration

  • Biotechnology & Pharmaceuticals
  • Medical Devices
  • Biofuels and Agricultural Biotechnology

Representative Experience

  • Assisted team on a patent interference for an ag-biotech company against a competitor; judgment resulted in invalidation of a key competitor patent
  • Performed due diligence analysis of the patent portfolio and IP landscape relative to a biofuel company as part of a proposed multi-million dollar investment in the company
  • Coordinated patent prosecution of a portfolio of applications for a new agricultural product scheduled for international commercial launched in 2011
  • Performed IP landscape analyses for a large biotech company to provide strategic advice regarding the possible components for commercial multivalent vaccine formulations

Professional Activities & Memberships

  • Austin Intellectual Property Law Association (AIPLA) (2011 – present)
  • Association of University Technology Managers (AUTM) (2010 – present)
  • American Association for the Advancement of Science (AAAS) (2003 – present)
  • U.S. Patent Bar since 2006


  • Byrd, M.P., Zamora, M., and Lloyd, RE., “Translation of eIF4GI proceeds from multiple mRNAs containing a novel cap-dependent IRES that is active during poliovirus infection,” J. Biol. Chem. 280(19):18610-18622, 2005
  • Sherrill K.W., Byrd M.P., Van Eden M.E. and Lloyd R.E., “BCL-2 Translation is mediated via internal ribosome entry during cell stress,” J. Biol. Chem. 279:29066-29074, 2004
  • Van Eden, M.E., Byrd, M.P., Sherrill, K.W., and Lloyd, R.E., “Demonstrating internal ribosome entry sites in eukaryotic mRNAs using stringent RNA test procedures,” RNA 10:720-730, 2004
  • Van Eden, M.E., Byrd, M.P., Sherrill, K.W., and Lloyd, R.E., “Translation of cellular inhibitor of apoptosis protein 1 (c-IAP1) mRNA is IRES-mediated and regulated during cell stress,” RNA 10:469-481, 2004
  • Byrd, M.P., Zamora M., and Lloyd, R.E., “Generation of Multiple Isoforms of Eukaryotic Translation Initiation Factor 4GI by Use of Alternate Translation Initiation Codons,” Mol. 22:4499 - 4511, 2002

Educational Background

  • 2005 – Ph.D., Molecular Biology, Baylor College of Medicine, Houston, TX
  • 1999 – B.A., Molecular, Cellular & Developmental Biology, University of Colorado, Boulder, CO